A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Inhaled MDT-637 Administered to Healthy Volunteers for 10 Days.
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2012
At a glance
- Drugs MDT 637 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 28 Sep 2012 Results were presented at the 8th Annual International Respiratory Syncytial Virus Symposium (RSV-2012), according to a MicroDose Therapeutx media release.
- 24 Apr 2012 Actual end date (Apr 2012) added as reported by MicroDose Therapeutx.
- 22 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.